AMSBIO has launched two new biotinylated formats of the 10E4 Heparan Sulfate antibody (high and low biotin) along with a starter pack to allow scientists to test both formats at a reduced cost.

Genomic sequencing service provider Macrogen Europe has achieved a significant upgrade to its next-generation sequencing capacity.

Memo Therapeutics AG has announced that MTX-COVAB, its human-derived antibody against SARS-CoV-2, the virus that causes COVID-19, has shown efficacy against both the original virus as well as the UK variant (B.1.1.7).

Sphere Fluidics has announced it has enhanced the capability and performance of its Cyto-Mine® System. The simplified design offers improved functionality to help streamline workflows, reduce costs, increase throughput, and enable high-value clones to be captured in a single run.

Oxford Immunotec has announced that its T-SPOT®.COVID test will be used for T cell testing in the COV-AD (COVID infection in patients with Antibody Deficiency) study in collaboration with the University of Birmingham.

Phico Therapeutics Ltd has announced £7 million in new investment. The financing was led by the UK’s most active growth capital investor, BGF which invested £3 million and was joined by other existing Phico investors.

Flow Eighteen38 and FairJourney Biologics S.A. have announced an agreement with the Hubrecht Institute to harness the potential of FJB’s proprietary llama naïve libraries to develop antibodies to be used as research tools.

Orgenesis Inc. announces it has been granted Investigational Device Exemption (IDE) approval by the United States Food and Drug Administration (FDA) to conduct a first-in-human feasibility study of the Tissue Genesis Icellator2(R) to treat Acute Respiratory Distress Syndrome (ARDS) resulting from COVID-19 infection.

Cherwell Laboratories is pleased to introduce new models to the ImpactAir range of microbial air monitors.

BellBrook Labs has been awarded a $1.8 million Phase II SBIR grant for the treatment of lupus and other autoimmune diseases.